



Press release

**New awarded projects and new contracts
for image interpretation and management in clinical trials
totaling €4.09M**

- ✓ Three projects awarded* -including two Phase III studies- sponsored by a European biotech company and a Top 25 pharmaceutical company.
- ✓ Two contracts signed for a Phase I/II study and a Phase II study sponsored by two European biotech companies.

SOPHIA ANTIPOLIS, France – October 13, 2015 – MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announced today that it has been selected to provide imaging solutions and services for five new clinical studies in oncology. These five new projects total approximately €4.09M and include the following:

- Awarded projects:
 - A phase III study (gastric cancer) for a total of €1.75M
 - A phase III study (rare and aggressive cutaneous cancer) for a total of €1.51M
 - A phase II study (melanoma) for a total of €335K
- Contracts:
 - A phase I/II study (liver cancer) for a total of €394K
 - A phase II study (primary central nervous system lymphoma) for a total of €103K

The five studies are sponsored by major European biotech companies that specialize in oncology and immuno-oncology and that are new MEDIAN Technologies' clients, and by one Top 25 pharmaceutical company, that is already a client for MEDIAN Technologies.

**A project award is a notification announcing that the company's solution has been selected for a specific project. This should result in a signed contract within 18 months, subject to upstream clinical results.*



About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors

worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.



Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. ISIN: FR0011049824– ticker: ALMDT The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechologies.com

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”



Contacts

MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com	Press ALIZE RP Caroline Carmagnol / Wendy Rigal + 33 1 44 54 36 66 median@alizerp.com	Investors ACTIFIN Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 11
--	---	---